TY - JOUR
T1 - Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL
AU - Vieira Martins, Miguel
AU - de Lorenzo, Paola
AU - Kotecha, Rishi S.
AU - Attarbaschi, Andishe
AU - Escherich, Gabriele
AU - Nysom, Karsten
AU - Stary, Jan
AU - Ferster, Alina
AU - Brethon, Benoit
AU - Locatelli, Franco
AU - Schrappe, Martin
AU - Houtem, Peggy E.Scholte van
AU - Valsecchi, Maria G.
AU - Pieters, Rob
AU - van der Sluis, Inge M.
N1 - Publisher Copyright:
© 2026 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.
PY - 2026
Y1 - 2026
N2 - Adding blinatumomab to standard chemotherapy for infants with KMT2A-rearranged acute B-cell lymphoblastic leukemia (KMT2A-r B-ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood. Thirty infants received Interfant-06 protocol chemotherapy with one course of blinatumomab added post-induction. We screened 169 IgG levels post-blinatumomab and IVIg supplementation timepoints. An increase in IgG was subsequently noted until maintenance, where practically all available values returned to normal (>4 g/L). Blinatumomab leads to an IgG reduction, with near-complete recovery occurring before end of treatment. Future trials should monitor immunoglobulin recovery post-blinatumomab to guide infection-preventing strategies. Trial Registration: EudraCT no: 2016-004674-17.
AB - Adding blinatumomab to standard chemotherapy for infants with KMT2A-rearranged acute B-cell lymphoblastic leukemia (KMT2A-r B-ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood. Thirty infants received Interfant-06 protocol chemotherapy with one course of blinatumomab added post-induction. We screened 169 IgG levels post-blinatumomab and IVIg supplementation timepoints. An increase in IgG was subsequently noted until maintenance, where practically all available values returned to normal (>4 g/L). Blinatumomab leads to an IgG reduction, with near-complete recovery occurring before end of treatment. Future trials should monitor immunoglobulin recovery post-blinatumomab to guide infection-preventing strategies. Trial Registration: EudraCT no: 2016-004674-17.
UR - https://www.scopus.com/pages/publications/105045565442
U2 - 10.1002/1545-5017.70547
DO - 10.1002/1545-5017.70547
M3 - Article
AN - SCOPUS:105045565442
SN - 1545-5009
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
ER -